Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kiora PharmaceuticalsKPRX +2.00%34 Debt-to-Equity is 0.03 as of Mar. 2026, which is 200% above its 10-year median of 0.01. GuruFocus rates KPRX with a GF Score™ of 34/100. The stock has 3 warning signs investors should review. Among 965 Biotechnology companies, Kiora Pharmaceuticals ranks better than 81.14% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Kiora Pharmaceuticals's Debt-to-Equity or its related term are showing as below:
KPRX'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.09 Med: 0.01 Max: 0.06
Current: 0.03
During the past 13 years, the highest Debt-to-Equity Ratio of Kiora Pharmaceuticals was 0.06. The lowest was -0.09. And the median was 0.01.
KPRX's Debt-to-Equity is ranked better than 81.14% of 965
companies
in the Biotechnology industry
Industry Median: 0.16
vs KPRX: 0.03
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Kiora Pharmaceuticals Debt-to-Equity Related Terms
Kiora Pharmaceuticals Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Kiora Pharmaceuticals's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KPRX vs PBM, AEON, XCUR: Debt-to-Equity Comparison
For the Biotechnology subindustry, Kiora Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kiora Pharmaceuticals Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kiora Pharmaceuticals's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Kiora Pharmaceuticals's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kiora Pharmaceuticals (KPRX) has a Debt-to-Equity of 0.03 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Kiora Pharmaceuticals and its competitors. This is 200% above median its historical median of 0.01. According to the industry distribution chart, Kiora Pharmaceuticals ranks #182 out of 965 companies in the Biotechnology industry, placing it in the top 18.9%.
Is Kiora Pharmaceuticals' Debt-to-Equity too high?
Kiora Pharmaceuticals' current Debt-to-Equity of 0.03 is 200% above median its 10-year median of 0.01. The Biotechnology industry median Debt-to-Equity is 0.16. Kiora Pharmaceuticals' value of 0.03 is 81.3% below this industry median. Based on the distribution chart, Kiora Pharmaceuticals ranks #182 out of 965 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Kiora Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Kiora Pharmaceuticals' Debt-to-Equity compare to PBM and AEON?
According to the Biotechnology industry distribution chart, Kiora Pharmaceuticals ranks #182 out of 965 companies for Debt-to-Equity. This places Kiora Pharmaceuticals in the top 19% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.16. Kiora Pharmaceuticals' value of 0.03 is 81.3% below this benchmark. While the company's 10-year median is 0.01 vs. the industry median of 0.16, Kiora Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kiora Pharmaceuticals's current Debt-to-Equity of 0.03 is 81.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Kiora Pharmaceuticals and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kiora Pharmaceuticals's current Debt-to-Equity is 0.03, which is 200% above median its own 10-year median of 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kiora Pharmaceuticals stock overvalued right now?
Kiora Pharmaceuticals (KPRX) has a current Debt-to-Equity of 0.03. The current Debt-to-Equity is 0.03, which is 200% above median its 10-year median of 0.01 and 81.3% below the Biotechnology industry median of 0.16. Kiora Pharmaceuticals' overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Kiora Pharmaceuticals (KPRX), the current Debt-to-Equity is 0.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
34GF Score
Get the complete analysis for KPRX
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KPRX has been successfully added to your 
